Next Generation Tumor Targets
Targeting novel tumor antigens for greater specificity and multifunctional anti-tumor activity.
A New Chapter
Synergy Immunotherapeutics (IMT), is dedicated to developing high-efficacy cancer treatments for patients in need. Novel multispecific immunotherapeutics are developed to target antigens that are restricted to tumor and/or certain cells within the tumor microenvironment (TME) with protumor activity.
A platform approach identifies these novel tumor antigens from patient blood that are cytoplasmic in normal cells but locate to the surface of tumor cells and stressed cells within the TME. The approach can enable the development of therapeutics with a more favorable Therapeutic Index relative to many clinical tumor targets.
Certain stress-induced tumor antigens (sTA) are identified that when targeted result in a significant decrease in tumor cell growth or survival, both in vitro and in vivo. The surface localization and activities of sTA can enable new strategies to overcome critical clinical challenges such as drug resistance and metastasis.
Emerging Therapeutic Solutions
Novel tumor antigens have been effectively targeted with monospecific antibodies, antibody drug conjugates (ADCs), T cell engagers (TCE) and with innovative multispecific recombinant antibodies and proteins. Given the properties of the tumor antigens, there is high potential for a novel adjuvant or stand-alone therapeutic and for synergy with certain approved cancer therapeutics to kill tumor cells and induce or revitalize an anti-tumor immune response. AI is integrated to accelerate and enhance development from discovery to investigative new drug.
